Navidea Receives Orphan Drug Designation from FDA for Use of Lymphoseek® in Head and Neck Cancers
September 18 2014 - 4:07PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today
announced that Lymphoseek® (technetium Tc 99m tilmanocept)
Injection has been granted Orphan Drug Designation by the U.S. Food
& Drug Administration (FDA) for use in sentinel lymph node
detection in patients with cancer of the head and neck. The
designation is based upon an estimated 40,000 procedures being
performed in this patient population. The FDA Office of Orphan
Products Development (OOPD) mission is to advance the evaluation
and development of products (drugs, biologics, devices, or medical
foods) that demonstrate promise for the diagnosis and/or treatment
of rare diseases or conditions.
“This Orphan Drug designation provides further validation of
Lymphoseek for sentinel lymph node detection, underscores the need
for new innovations in the treatment of patients with head and neck
cancer, and, importantly strengthens Navidea’s competitive position
by providing seven years of market exclusivity in this indication,"
said Michael Goldberg M.D., Navidea Interim CEO. "This decision
follows the FDA Fast Track designation, Priority Review and
subsequent sNDA approval of Lymphoseek for guiding sentinel lymph
node biopsy in head and neck cancer patients with squamous cell
carcinoma of the oral cavity.”
The FDA Orphan Drug Designation program provides a special
status to drugs and biologics intended to treat, diagnose or
prevent rare, or ‘orphan’, diseases and disorders, defined as
affecting fewer than 200,000 people in the U.S. This designation
provides for a seven-year marketing exclusivity period against
competition in head and neck cancers as well as certain incentives,
including federal grants, tax credits and a waiver of PDUFA filing
fees, which qualifies the Company to request a refund of previously
paid filing fees of up to $1.1 million.
About Lymphoseek®Lymphoseek® (technetium Tc 99m
tilmanocept) Injection is the first and only FDA-approved
receptor-targeted lymphatic mapping agent. It is a novel,
receptor-targeted, small-molecule radiopharmaceutical used in the
evaluation of lymphatic basins that may have cancer involvement in
patients with breast cancer, melanoma and head and neck cancer
patients with oral cavity carcinoma. Lymphoseek is designed for the
precise identification of lymph nodes that drain from a primary
tumor, which have the highest probability of harboring cancer.
Lymphoseek is approved by the U.S. Food and Drug Administration
(FDA) for use in lymphatic mapping to assist in the localization of
lymph nodes draining a primary tumor in patients with breast cancer
or melanoma and for use in guiding sentinel lymph node biopsy in
head and neck cancer patients with squamous cell carcinoma of the
oral cavity. The Company anticipates continuing development of
Lymphoseek into other solid tumor areas.
Lymphoseek Indication and Important Safety
InformationLymphoseek (technetium Tc 99m tilmanocept) Injection
is indicated, using a hand-held gamma counter, for:
- Lymphatic mapping to assist in the
localization of lymph nodes draining a primary tumor site in
patients with breast cancer or melanoma;
- Guiding sentinel lymph node biopsy, in
patients with clinically node negative squamous cell carcinoma
(SCC) of the oral cavity.
Important Safety InformationIn clinical trials with
Lymphoseek, no serious hypersensitivity reactions were reported,
however Lymphoseek may pose a risk of such reactions due to its
chemical similarity to dextran. Serious hypersensitivity reactions
have been associated with dextran and modified forms of dextran
(such as iron dextran drugs).
Prior to the administration of Lymphoseek, patients should be
asked about previous hypersensitivity reactions to drugs, in
particular dextran and modified forms of dextran. Resuscitation
equipment and trained personnel should be available at the time of
Lymphoseek administration, and patients observed for signs or
symptoms of hypersensitivity following injection.
Any radiation-emitting product may increase the risk for cancer.
Adhere to dose recommendations and ensure safe handling to minimize
the risk for excessive radiation exposure to patients or health
care workers. In clinical trials, no patients experienced serious
adverse reactions and the most common adverse reactions were
injection site irritation and/or pain (<1%).
Full Lymphoseek Prescribing Information Can Be Found at:
WWW.LYMPHOSEEK.COM.
About Navidea Biopharmaceuticals Inc.Navidea
Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of
precision diagnostics and radiopharmaceutical agents. Navidea is
developing multiple precision diagnostic products and platforms
including Manocept™, NAV4694, NAV5001, and NAV1800 (RIGScan™), to
help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and,
ultimately, patient care. Lymphoseek® (technetium Tc 99m
tilmanocept) Injection, Navidea’s first commercial product from the
Manocept platform, was approved by the FDA in March 2013. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
Navidea BiopharmaceuticalsBrent Larson, Executive VP & CFO,
614-822-2330orSharon Correia, Associate Director, Corporate
Communications, 978-655-2686
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024